Nomura Maintains a Buy Rating on Galapagos (GLPG)

Nomura analyst Christopher Marai maintained a Buy rating on Galapagos (GLPG) yesterday and set a price target of $290.00. The company’s shares closed last Monday at $238.08.

According to, Marai is a 4-star analyst with an average return of 3.2% and a 47.3% success rate. Marai covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Protagonist Therapeutics, and Alexion Pharmaceuticals.

Currently, the analyst consensus on Galapagos is a Hold with an average price target of $235.30, a -4.8% downside from current levels. In a report issued on February 21, Cowen & Co. also maintained a Buy rating on the stock.

See today’s analyst top recommended stocks >>

Based on Galapagos’ latest earnings release for the quarter ending September 30, the company reported a quarterly net profit of $402 million. In comparison, last year the company had a net profit of $17.07 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. It operates through the Research and Development and Fee-for-Services segment. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts